Tempus and Pfizer Present AI Diagnostic Study Results at ESMO Congress
What happened
Tempus and Pfizer presented study results at the European Society for Medical Oncology Congress 2026 in Madrid. The study evaluated more than 60,000 advanced non-small cell lung cancer (NSCLC) cases. The AI-enabled pre-screening panel achieved greater than 80% sensitivity across all 12 biomarkers assessed, with sensitivity exceeding 90% for several biomarkers, using routine H&E pathology images.
From finanznachrichten.de
Why it matters
The findings support the potential for AI to help clinicians prioritize diagnostic testing and accelerate access to clinically actionable results. This technology is designed to increase the number of patients who receive appropriate biomarker testing and preserve limited tissue samples.
From finanznachrichten.de
Who's involved
- TempusBiotechnology company collaborating with Pfizer on addressing diagnostic barriers.
- PfizerMultinational pharmaceutical corporation collaborating with Tempus on diagnostic barriers.
- European Society for Medical OncologyProfessional organization hosting the presentation of study results.
Keep exploring
The entities involved
-
Tempus
biotechnology company based in Chicago, Illinois
Nothing else this week.
-
Pfizer
American multinational pharmaceutical and biotechnology corporation
-
European Society for Medical Oncology
Professional organisation
Related events
- Researchers presented Phase 3 clinical data at the European Society for Medical Oncology (ESMO) Congress on September 21, 2026.
- Eli Lilly and Company presented oncology data at the European Society for Medical Oncology (ESMO) Congress.
- AbbVie presented clinical data at the European Society for Medical Oncology (ESMO) Congress held in Madrid.
- Faron Pharmaceuticals presented clinical data at the ESMO Congress on October 19, 2026.